Natera (NASDAQ:NTRA) Stock: Insider Michael Burkes Brophy Sells 781 Shares

Natera, Inc. (NASDAQ:NTRA) CFO Michael Brophy sold 781 shares of the company’s stock in a transaction that occurred on Tuesday, October 27th. The stock was sold at an average price of $406.00, for a total value of $317,086.00. Following the transaction, the chief financial officer owned 50,856 shares of the company’s stock, valued at approximately $20,647,536. This trade represents a 1.51% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Michael Burkes Brophy also recently made the following trade(s):

• On Wednesday, October 28th, Michael Brophy sold 1,198 shares of Natera stock. The shares were sold at an average price of $426.34, for a total value of $510,755.32.
• On Tuesday, August 4th, Michael Brophy sold 478 shares of Natera stock. The stock was sold at an average price of $274.22, for a total transaction of $131,077.16.
• On Monday, August 3rd, Michael Brophy sold 317 shares of Natera stock. The stock was sold at an average price of $267.99, for a total transaction of $84,952.83.

Natera Trading Up 2.7%

NTRA stock traded up $11.58 on Thursday, reaching $436.00. 1,325,469 shares of the company were exchanged, compared to its average volume of 1,585,948. Natera, Inc. has a 12 month low of $181.00 and a 12 month high of $437.41. The stock’s fifty day moving average price is $375.27 and its 200 day moving average price is $265.54.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.02. The firm had revenue of $752.75 million during the quarter, compared to the consensus estimate of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The business’s revenue was up 37.7% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.74) EPS. As a group, sell-side analysts predict that Natera, Inc. will post -1.14 EPS for the current year.

Hedge Funds Weigh In On Natera

A number of hedge funds have recently modified their holdings of the stock. BlackRock Inc. bought a new stake in Natera in the second quarter valued at $2,962,770,000. Arrowstreet Capital Limited Partnership lifted its holdings in shares of Natera by 1.0% during the first quarter. Arrowstreet Capital Limited Partnership now owns 1,191,732 shares of the medical research company’s stock valued at $238,334,000 after acquiring an additional 11,793 shares during the period. Maverick Capital Ltd. lifted its holdings in shares of Natera by 24.1% during the first quarter. Maverick Capital Ltd. now owns 1,171,633 shares of the medical research company’s stock valued at $234,315,000 after acquiring an additional 227,605 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Natera by 10.7% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 833,376 shares of the medical research company’s stock valued at $226,220,000 after acquiring an additional 80,440 shares during the period. Finally, Bank of America Corp DE acquired a new stake in shares of Natera in the 2nd quarter valued at $199,960,000. 99.90% of the stock is owned by institutional investors and hedge funds.

More Natera News

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera presented 25 abstracts at the ESMO oncology conference, highlighting additional Signatera data and supporting the test’s potential commercial and clinical adoption. Natera presents 25 ESMO abstracts
• Positive Sentiment: Investors reacted favorably to Signatera clinical and regulatory wins, which could strengthen Natera’s competitive position in minimal residual disease testing and support future revenue growth. Investors React to Signatera Wins
• Positive Sentiment: The third-quarter outlook centers on continued Signatera volume growth, higher test prices, regulatory progress and expanding Medicare coverage that could benefit Natera’s organ-health business. NTRA Q3 Earnings Preview
• Neutral Sentiment: Natera will release third-quarter 2026 results on November 5 after the market closes, giving investors a near-term catalyst to assess testing volumes, reimbursement trends and profitability. Natera Q3 Results Announcement
• Negative Sentiment: Zacks cautions that Natera may report negative earnings and lacks the typical combination of estimate revisions and momentum associated with a likely earnings beat, raising the risk of volatility around the report. Natera Earnings Beat Outlook
• Negative Sentiment: One valuation analysis estimates NTRA could be about 32% below fair value based on ESMO-related data, suggesting the stock’s gains may have outpaced its fundamentals. Natera Fair Value Analysis
• Negative Sentiment: Two company officers disclosed plans to sell a combined 1,768 shares, including 771 shares valued at approximately $312,000; the transactions are relatively small but may modestly weigh on sentiment. John Fesko Share Sale Solomon Moshkevich Share Sale

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. Evercore reiterated an “outperform” rating and issued a $300.00 target price on shares of Natera in a research note on Monday, July 6th. Zacks Research lowered Natera from a “hold” rating to a “strong sell” rating in a research note on Friday, October 16th. Royal Bank Of Canada upped their price target on Natera from $350.00 to $460.00 and gave the company an “outperform” rating in a report on Friday, September 25th. JPMorgan Chase & Co. upped their price target on Natera from $360.00 to $460.00 and gave the company an “overweight” rating in a report on Wednesday, October 14th. Finally, Leerink Partners set a $330.00 price objective on Natera in a research report on Friday, August 7th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $394.31.

Natera Company Profile

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.